Ponikowski, Piotr

N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes

Ezekowitz, J. A., O’Connor, C. M., Troughton, R. W., Alemayehu, W. G., Westerhout, C. M., Voors, A. A., Butler, J., Lam, C. S. P., Ponikowski, P., Emdin, M., et al. (2020) · JACC: Heart Failure

Heart Failure Treatment and ManagementCardiac Fibrosis and Remodeling

Cited by 146

Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)

Serenelli, M., Böhm, M., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Solomon, S. D., DeMets, D. L., et al. (2020) · European Heart Journal

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 138

Anaemia is an independent predictor of poor outcome in patients with chronic heart failure

Szachniewicz, J., Petruk-Kowalczyk, J., Majda, J., Kaczmarek, A., Reczuch, K., Kalra, P. R., Piepoli, M. F., Anker, S. D., Banasiak, W., & Ponikowski, P. (2003) · International Journal of Cardiology

Erythropoietin and Anemia TreatmentHeart Failure Treatment and Management

Cited by 138

The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the Studies Investigating Co-morbidities Aggravating Heart Failure

Ebner, N., Jankowska, E. A., Ponikowski, P., Lainscak, M., Elsner, S., Sliziuk, V., Steinbeck, L., Kube, J., Bekfani, T., Scherbakov, N., et al. (2016) · International Journal of Cardiology

Erythropoietin and Anemia TreatmentIron Metabolism and Disorders

Cited by 131

Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes: A Mediation Analysis

Agarwal, R., Tu, W., Farjat, A. E., Farag, Y. M. K., Toto, R., Kaul, S., Lawatscheck, R., Rohwedder, K., Ruilope, L. M., Rossing, P., et al. (2023) · Annals of Internal Medicine

Chronic Kidney Disease and DiabetesHormonal Regulation and Hypertension

Cited by 109

Effect of Dapagliflozin on Outpatient Worsening of Patients With Heart Failure and Reduced Ejection Fraction: A Prespecified Analysis of DAPA-HF

Docherty, K. F., Jhund, P. S., Anand, I., Bengtsson, O., Böhm, M., de Boer, R. A., DeMets, D. L., Desai, A. S., Drozdz, J., Howlett, J., et al. (2020) · Circulation

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 95

Clinical correlates and prognostic impact of impaired iron storage versus impaired iron transport in an international cohort of 1821 patients with chronic heart failure

Moliner, P., Jankowska, E. A., van Veldhuisen, D. J., Farre, N., Rozentryt, P., Enjuanes, C., Polonski, L., Meroño, O., Voors, A. A., Ponikowski, P., et al. (2017) · International Journal of Cardiology

Iron Metabolism and DisordersErythropoietin and Anemia Treatment

Cited by 67

Patient journey after admission for acute heart failure: length of stay, 30-day readmission and 90-day mortality

Davison, B. A., Metra, M., Senger, S., Edwards, C., Milo, O., Bloomfield, D. M., Cleland, J. G., Dittrich, H. C., Givertz, M. M., O’Connor, C. M., et al. (2016) · European Journal of Heart Failure

Heart Failure Treatment and ManagementAcute Myocardial Infarction Research

Cited by 67

Central and peripheral determinants of exercise capacity in heart failure patients with preserved ejection fraction

Wolsk, E., Kaye, D., Komtebedde, J., Shah, S. J., Borlaug, B. A., Burkhoff, D., Kitzman, D. W., Lam, C. S. P., van Veldhuisen, D. J., Ponikowski, P., et al. (2019) · JACC Heart Failure

Cardiovascular and exercise physiologyHeart Failure Treatment and Management

Cited by 43

Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis

Teerlink, J. R., Davison, B. A., Cotter, G., Maggioni, A. P., Sato, N., Chioncel, O., Ertl, G., Felker, G. M., Filippatos, G., Greenberg, B. H., et al. (2020) · European Journal of Heart Failure

Heart Failure Treatment and ManagementCardiac Fibrosis and Remodeling

Cited by 41

Efficacy and Safety of Sodium–Glucose Co-Transporter 2 Inhibition According to Left Ventricular Ejection Fraction in DAPA-HF

Dewan, P., Solomon, S. D., Jhund, P. S., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., DeMets, D. L., Sabatine, M. S., et al. (2020) · European Journal of Heart Failure

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 41